MAM
ELVN icon

Marquette Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Marquette Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,436
Closed -$154K – 218
2022
Q4 		$154K Sell
9,436
-3,456
-27% -$55.2K 0.05% 82
2022
Q3 		$118K Sell
12,892
-6,753
-34% -$39.9K 0.04% 95
2022
Q2 		$96K Buy
+19,645
New +$96.1K 0.03% 132

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Marquette Asset Management's ELVN Position: Q1 2023 in Review

Marquette Asset Management sold out of Enliven Therapeutics (ELVN) in Q1 2023, closing a stake of 9,436 shares — an estimated $154K sold.

Marquette Asset Management first reported a position in ELVN in Q2 2022 and held it in 3 quarters. The position peaked at $154K in Q4 2022. 45 funds tracked by Wall St. Rank hold ELVN as of Q1 2023.

  • Marquette Asset Management reported no remaining Enliven Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Marquette Asset Management sold 9,436 Enliven Therapeutics shares in Q1 2023, an estimated $154K.
  • Marquette Asset Management first reported a position in Enliven Therapeutics in Q2 2022 and held it in 3 quarters.
  • Marquette Asset Management's Enliven Therapeutics position peaked at $154K in Q4 2022.
  • 45 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2023.

Based on Marquette Asset Management's 13F filing for Q1 2023, filed 1 May 2023.